Supplementary Table 2 from Inhibition of TGF-β Enhances the <i>In Vivo</i> Antitumor Efficacy of EGF Receptor–Targeted Therapy

Abstract

&lt;p&gt;PDF file - 70K, A, Serum levels of the indicated cytokines in patients with HNSCC and pleomorphic adenoma (non-cancer control). B, Comparison of serum TGF-beta1 levels in non-cancer controls and patients with HNSCC at the time of new diagnosis and at the time of recurrence. C, Comparison of serum levels of TGF-beta1 in patients with HPV-negative HNSCC at the time of diagnosis, and at two time points after the completion of treatment&lt;/p&gt;